Meghan Migeon is the program director and an associate professor in the PA program at Springfield (Mass.) College. The author has disclosed no potential conflicts of interest, financial or otherwise.
JAAPA. 2021 Dec 1;34(12):54-56. doi: 10.1097/01.JAA.0000794984.26635.42.
A review of the recent literature found that compared with placebo or other pain medications, gabapentin did not significantly reduce nonneuropathic pain. The drug also is associated with an increased risk of adverse reactions, including somnolence, dizziness, and nausea. Given the lack of efficacy and risk of adverse reactions, gabapentin should not be used for nonneuropathic pain.
一篇综述文献回顾发现,与安慰剂或其他止痛药相比,加巴喷丁并没有显著减轻非神经性疼痛。该药物还与不良反应风险增加相关,包括嗜睡、头晕和恶心。鉴于疗效不佳和不良反应风险,加巴喷丁不应用于非神经性疼痛。